# Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

> **NCT03509545** · PHASE1 · TERMINATED · sponsor: **Sarfez Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Body Weight Changes

## Interventions

- **DRUG:** CHF Patients: ER Torsemide 40 mg
- **DRUG:** CHF Patients: Furosemide 40 mg

## Key facts

- **NCT ID:** NCT03509545
- **Lead sponsor:** Sarfez Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-30
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** recruitment issues
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509545, "Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03509545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*